

Needle for pen-injectors

# The World's Thinnest Double Tapered Pen Needle<sup>2</sup>




## Because You Care

## Less painful<sup>3</sup> insulin injection

Diabetes patients have long been in search of less painful<sup>3</sup> insulin injection. Terumo has made this possible with the advanced NANOPASS 34 – the world's thinnest double tapered pen needle<sup>2</sup> with a diameter of only 34G.

## NANOPASS 34 reduces pain<sup>3</sup> through several advanced technologies:

- 1 World's thinnest double tapered pen needle "34G"2
- 2 Asymmetric edge<sup>4</sup>
- 3 Slim double tapered shape4



## World's thinnest double tapered pen needle "34G"<sup>2</sup> NANOPASS 34 is 22% thinner than 32G.

- Pain is primarily related to needle thickness. There are 100-200 pain receptors per cm<sup>2</sup> human skin surface. NANOPASS 34 decreases the probability of touching the pain receptors and therefore makes the insulin injection less painful<sup>3</sup>.
- NANOPASS 34 causes less skin trauma than larger needle sizes, which results in less pain<sup>3</sup>.
















# NANOPASS

Less pain<sup>3</sup>, every day

## 2 Asymmetric edge<sup>4</sup>

The unique asymmetric edge<sup>4</sup> of NANOPASS 34 cuts the skin instead of puncturing it. This decreases the resistance while penetrating the skin. Another step towards less painful<sup>3</sup> insulin injection.





### 3 Slim double tapered shape4

The patented slim double tapered needle shape<sup>4</sup> reduces the insulin injection force significantly. Although the needle tip is 34G, NANOPASS 34 provides less injection force than a conventional 32G pen needle<sup>3</sup>.



## NANOPASS 34G

## Pen needle fits all common pen-injectors.5











Pen needle with screw thread



Inner and outer needle cap

#### Specifications

Product Code	TN*3404M
Needle tip diameter	34G (Ø 0.18 mm)
Needle length	4 mm
Packaging size	100 pieces





Does not contain components made of natural rubber latex.

- 1 Terumo Corporation has launched Nanopass 34G in September 2012.
- 2 Based on research by Terumo Corporation in May 2017.
- 3 Asakura T., Seino H., 2013, Jpn J Med Pharm Sci 69(1):137-146. & Asakura T., 2013, Jpn J Med Pharm Sci 69(1):147-155.
- 4 Patented technology.
- 5 For detailed list of compatible devices see NANOPASS pen needle boxes.

#### Visit www.terumo-diabetes.com



**Terumo Corporation** +81 3 3374 8111

Terumo Europe NV

+32 16 38 12 11

EMEA Sales Offices

**Terumo Europe NV** Africa Business Division

+32 16 38 13 08

Terumo Europe NV **Benelux Sales Division** 

Belgium:

+32 16 39 25 80 The Netherlands: 0800 0220396

Terumo Europe NV Emerging Market Division

+32 16 38 12 11

Terumo Deutschland GmbH

+49 6196 80 230

**Terumo Deutschland GmbH** Switzerland +41 56 419 10 10

Terumo Europe España SL

+34 902 10 12 98

Terumo France S.A.S. +33 130 96 13 00

Terumo Italia S.r.I.

+39 06 94 80 28 00

Terumo Russia LLC +7 495 988 4740

Terumo Sweden AB

+46 3174 85 880

Terumo Sweden AB Denmark

+45 7020 93 80

Terumo Middle East FZE

+971 4 292 0200

Terumo UK Ltd +44 1276 480 440

Terumo BCT Tıbbi Cihazlar Dağıtım ve Hizmetleri A.Ş. +90 216 590 0074



® Registered Trademark Published by Terumo Europe NV DI 102GB-0917FK-III(09.17)E

www.terumo-europe.com